Status:
TERMINATED
A Study of Circulating Endothelial Cell as Marker for Avastin (Bevacizumab) in Combination With Docetaxel Plus Xeloda (Capecitabine) as First Line Treatment for Patients With Locally Recurrent and Metastatic Breast Cancer
Lead Sponsor:
Hoffmann-La Roche
Conditions:
Breast Cancer
Eligibility:
FEMALE
18-65 years
Phase:
PHASE2
Brief Summary
This single arm study will evaluate the correlation between circulating endothelial cell levels and treatment efficacy in patients with locally recurrent and metastatic breast cancer given first line ...
Eligibility Criteria
Inclusion
- female patients, 18-65 years of age;
- locally recurrent and metastatic breast cancer;
- measurable or evaluable disease;
- ECOG performance status of 0-2;
- LVEF \>=50% without clinical symptoms or signs of heart failure.
Exclusion
- unknown HER2 status, or known HER2-positive status;
- prior chemotherapy for locally recurrent or metastatic disease;
- prior adjuvant or neoadjuvant taxane therapy within 12 months prior to start of treatment;
- clinical or radiological evidence of CNS metastases;
- clinically significant cardiovascular disease.
Key Trial Info
Start Date :
May 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2011
Estimated Enrollment :
22 Patients enrolled
Trial Details
Trial ID
NCT00845910
Start Date
May 1 2009
End Date
May 1 2011
Last Update
November 2 2016
Active Locations (4)
Enter a location and click search to find clinical trials sorted by distance.
1
Kaohsiung City, Taiwan, 807
2
Taichung, Taiwan, 404
3
Taichung, Taiwan, 407
4
Taoyuan District, Taiwan, 333